Leerink Maintains Outperform on Cardinal Health, Inc. (CAH) March 2026

Leerink Partners on March 9, 2026 maintained an Outperform on Cardinal Health, Inc. (CAH). This CAH analyst rating confirms Leerink’s view that the company is positioned for solid fiscal second‑half 2026 growth. The note caused a modest market reaction, with a 0.11% ($0.25) move reported after the reiteration. No new price target was published in the note. We review the analyst action, context, and what the CAH analyst rating means for investors and stock risk.